DOCSLIB.ORG

PMBJP Product.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Sr. Drug Generic Name of the Medicine Unit Size MRP Therapeutic Category No. Code Analgesic & Antipyretic / Muscle 1 1 Aceclofenac 100mg and Paracetamol 325 mg Tablet 10's 10's 8.00 relaxants Analgesic & Antipyretic / Muscle 2 2 Aceclofenac Tablets IP 100mg 10's 10's 4.37 relaxants Acetaminophen 325 + Tramadol Hydrochloride 37.5 film Analgesic & Antipyretic / Muscle 3 4 10's 8.00 coated Tablet 10's relaxants Analgesic & Antipyretic / Muscle 4 5 ASPIRIN Tablets IP 150 mg 14's 14's 2.70 relaxants DICLOFENAC 50 mg+ PARACETAMOL 325 mg+ Analgesic & Antipyretic / Muscle 5 6 10's 11.30 CHLORZOXAZONE 500 mg Tablets 10's relaxants Diclofenac Sodium 50mg + Serratiopeptidase 10mg Tablet Analgesic & Antipyretic / Muscle 6 8 10's 12.00 10's relaxants Analgesic & Antipyretic / Muscle 7 9 Diclofenac Sodium (SR) 100 mg Tablet 10's 10's 6.12 relaxants Analgesic & Antipyretic / Muscle 8 10 Diclofenac Sodium 25mg per ml Inj. IP 3 ml 3 ml 2.00 relaxants Analgesic & Antipyretic / Muscle 9 11 Diclofenac Sodium 50 mg Tablet 10's 10's 2.90 relaxants Analgesic & Antipyretic / Muscle 10 12 Etoricoxilb Tablets IP 120mg 10's 10's 33.00 relaxants Analgesic & Antipyretic / Muscle 11 13 Etoricoxilb Tablets IP 90mg 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 12 14 Ibuprofen 400 mg + Paracetamol 325 mg Tablet 10's 15's 5.50 relaxants Analgesic & Antipyretic / Muscle 13 15 Ibuprofen 200 mg film coated Tablet 10's 10's 1.80 relaxants Analgesic & Antipyretic / Muscle 14 16 Ibuprofen 400 mg film coated Tablet 10's 15's 3.50 relaxants Analgesic & Antipyretic / Muscle 15 20 Nimesulide BP 100 mg Tablet 10's 10's 4.10 relaxants Diclofenac Sodium 50 mg and Paracetamol 325 mg Tablet Analgesic & Antipyretic / Muscle 16 21 10's 6.87 10's relaxants 60 ml Analgesic & Antipyretic / Muscle 17 22 Paracetamol Syrup IP 125mg/5ml 60 ml 10.60 bottles relaxants Analgesic & Antipyretic / Muscle 18 23 Paracetamol Tablets IP 500mg 10's 10's 4.51 relaxants Analgesic & Antipyretic / Muscle 19 24 Pentazocine Injection IP 30mg/ml 1 ml 1ml 2.70 relaxants Analgesic & Antipyretic / Muscle 20 25 Serratiopeptidase 10 mg Tablet 10's 10's 8.90 relaxants Analgesic & Antipyretic / Muscle 21 26 Tramadol Hcl 100 mg Inj. 2ml 2ml 6.32 relaxants Analgesic & Antipyretic / Muscle 22 27 Tramadol HCl Injection 50mg 1 ml 1 ml 1ml 4.30 relaxants Analgesic & Antipyretic / Muscle 23 28 Tramadol 50 mg Tablet 10's 10's 4.90 relaxants Analgesic & Antipyretic / Muscle 24 336 Allopurinol 100 mg Tablet 10's 10's 8.60 relaxants DICYCLOMINE 10 mg+ MEFENAMIC ACID 250 mg Analgesic & Antipyretic / Muscle 25 467 10's 8.40 Tablets 10's relaxants Analgesic & Antipyretic / Muscle 26 509 HYDROXYCHLOROQUINE Tablets IP 200 mg 10's 10's 30.00 relaxants PARACETAMOL 325 mg+ TRAMADOL 37.5 mg Tablets Analgesic & Antipyretic / Muscle 27 510 10's 8.50 10's relaxants Analgesic & Antipyretic / Muscle 28 511 PARACETAMOL Tablets IP 650 mg 15's 15's 8.03 relaxants Aceclofenac 100 mg + Paracetamol 325 mg + Analgesic & Antipyretic / Muscle 29 512 10's 12.60 Serratiopeptidase 15 mg Tablets 10's relaxants Analgesic & Antipyretic / Muscle 30 513 PIROXICAM Capsules IP 20 mg 10's 10's 6.75 relaxants Analgesic & Antipyretic / Muscle 31 515 MEFENAMIC ACID SUSPENSION 100 mg/5 ml 60 ml 60 ML 14.92 relaxants Analgesic & Antipyretic / Muscle 32 516 ACECLOFENAC Tablets SR/CR 200 mg 10's 10's 11.90 relaxants THIOCOLCHICOSIDE 4 mg+ ACECLOFENAC 100 mg Analgesic & Antipyretic / Muscle 33 517 10's 36.67 Tablets 10's relaxants Analgesic & Antipyretic / Muscle 34 518 BACLOFEN Tablets IP 10 mg 10's 10's 12.90 relaxants Analgesic & Antipyretic / Muscle 35 519 Ketorolac Tromethamine Tablets IP 10mg 10's 10's 7.65 relaxants MEFENAMIC ACID 500 MG+ PARACETAMOL 325 MG Analgesic & Antipyretic / Muscle 36 520 10's 14.80 TABLETS 10's relaxants Analgesic & Antipyretic / Muscle 37 521 TRAMADOL TABLETS SR 100 MG 10's 10.20 relaxants Analgesic & Antipyretic / Muscle 38 522 ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG 10's 19.90 relaxants PARACETAMOL 325mg+ PHENYLEPHRINE 10 mg+ Analgesic & Antipyretic / Muscle 39 528 10's 16.00 CHLORPHENIRAMINE 2 mg Tablets 10's relaxants Cetirizine Dihydrochloride IP 5mg, Phenylephrine HCl IP 10 Analgesic & Antipyretic / Muscle 40 603 10s 7.65 mg, Paracetamol IP 325mg Tablets 10's 10's relaxants Diclofenac Potassium BP 50mg + Paracetamol 325mg + Analgesic & Antipyretic / Muscle 41 613 10's 9.22 Serratiopeptidase 10mg Tablets 10's 10's relaxants Aceclofenac 100 mg + Paracetamol 325 mg + Chorzoxazone Analgesic & Antipyretic / Muscle 42 637 10's 12.30 250 mg film coated tab. 10's relaxants Paracetamol 125mg+ CPM 1 mg + Sodium Citrate 60mg in a 60 ml Analgesic & Antipyretic / Muscle 43 643 12.19 flavour syrup base 60 ML Bottles Bottle relaxants Paracetamol IP…125 mg., Mefanamic Acid IP…50 mg., in a Analgesic & Antipyretic / Muscle 44 651 60 ml. 11.00 flavoured syrupy base…q.s. 60 ML relaxants Analgesic & Antipyretic / Muscle 45 652 Dicyclomine 10mg + Mefenamic 250mg Tablets 10's 10's 10's 6.09 relaxants Paracetamol I.P. 125mg, Promethazine HCl I.P. 5mg Analgesic & Antipyretic / Muscle 46 667 60ml 7.76 Suspension 15 ml 15 ml relaxants Diacerein 50 mg +Methylsulphonylmethane 250 mg + Analgesic & Antipyretic / Muscle 47 670 10's 36.80 Glucosamine sulphate 750 mg tab. 10's relaxants Diacerein 50mg + Glucosamine Sulphate 500mg Tablets 10's Analgesic & Antipyretic / Muscle 48 671 10's 34.93 10's relaxants Analgesic & Antipyretic / Muscle 49 702 Haloperidol 0.5 mg Tablet. 10's 10's 7.50 relaxants Analgesic & Antipyretic / Muscle 50 708 Piroxicam 20 mg btablets 10's 10's 12.00 relaxants Analgesic & Antipyretic / Muscle 51 709 Piroxicam 20 mg with bezyl alcohol injection 1ml 1ml 4.74 relaxants Analgesic & Antipyretic / Muscle 52 710 Piroxicam 40 mg with bezyl alcohol injection 2ml 2ml 5.69 relaxants Analgesic & Antipyretic / Muscle 53 712 Paracetamol DS syrup /250 mg 60ml 60ml 10.19 relaxants Analgesic & Antipyretic / Muscle 54 717 Etodolac Tablets IP 300mg 10's 10's 10's 25.00 relaxants Analgesic & Antipyretic / Muscle 55 865 Diacerein Capsules IP 50mg 10's 41.00 relaxants Analgesic & Antipyretic / Muscle 56 868 Dicyclomine HCl (Dicycloverine) Injection IP 10mg/ml 2ml 3.49 relaxants Analgesic & Antipyretic / Muscle 57 888 Febuxostat Tablets 40mg 10's 16.60 relaxants Analgesic & Antipyretic / Muscle 58 889 Febuxostat Tablets 80mg 10's 10's 32.00 relaxants Analgesic & Antipyretic / Muscle 59 933 Leflunomide Tablets IP 20mg 10's 10's 66.38 relaxants Analgesic & Antipyretic / Muscle 60 955 Mefenamic Acid 50mg, Paracetamol 125mg/5ml Suspension 60ml 11.00 relaxants Analgesic & Antipyretic / Muscle 61 1081 Tizanidine Tablets I.P 2mg 10's 10's 21.20 relaxants Analgesic & Antipyretic / Muscle 62 1135 Diacerein 50 mg + Glucosamine Sulphate 750 mg Tablets 10's 10's 45.00 relaxants Analgesic & Antipyretic / Muscle 63 1167 MEFENAMIC ACID 500 MG TABLETS 10's 10's 11.00 relaxants 60 ml 64 239 Cetirizine (5 mg/ 5 ml) Syrup 60 ml 9.60 Antiallergic bottles 65 240 Cetrizine 10mg film coated Tablet 10's 10's 2.00 Antiallergic Pheniramine Maleate I.P. 22.75mg,Methyl Paraben(as 66 666 2ml 5.27 Antiallergic preservative) I.P. 0.135% w/v, Propyl Paraben(as 2 ML 67 881 Ebastine Film Coated Tablets 10mg 10's 7.16 Antiallergic 68 915 Hydroxyzine HCl Tablets IP 10mg 10's 4.04 Antiallergic 300.0 69 152 Bleomycin Injection IP 15mg Vial Vial & wfi Anticancer/Oncology 0 70 153 Cisplatin Injection IP10 mg Vial Vial 31.25 Anticancer/Oncology 165.0 71 154 Cisplatin Injection BP 50mg/50ml Vial Vial Anticancer/Oncology 0 72 155 Doxorubicin 10 mg Inj. Vial Vial 76.50 Anticancer/Oncology 250.5 73 156 Doxorubicin Injection IP 50mg Vial Vial Anticancer/Oncology 0 74 158 Etoposide 100 mg/5ml Inj. Vial Vial & wfi 76.06 Anticancer/Oncology 760.0 75 159 Gemcitabine 1000 mg Inj. Vial Vial Anticancer/Oncology 0 182.0 76 160 Gemcitabine Injection IP 200mg Vial Vial Anticancer/Oncology 0 77 163 Tamoxifen Citrate 10 mg I.P Tablets 10's 10's 9.56 Anticancer/Oncology 78 164 Tamoxifen Citrate 20 mg I.P Tablets 10's 10's 13.50 Anticancer/Oncology 127.0 79 736 Megestrol Acetate Tablets IP 40mg 10's 10's Anticancer/Oncology 0 80 788 Anastrozole Tablets IP 1mg 10's 77.40 Anticancer/Oncology 131.0 81 806 Bicalutamide Tab I.P 50mg 10's 10's Anticancer/Oncology 0 3188. 82 809 Bortezomib Injection 3.5 mg Vial Vial Anticancer/Oncology 00 420.0 83 819 Capecitabine Tab I.P 500mg 10's Anticancer/Oncology 0 188.0 84 851 Dacarbazine Injection 200mg VIAL Vial Anticancer/Oncology 0 204.0 85 853 Daunorubicin HCl Injection 20mg vial Vial Anticancer/Oncology 0 345.8 86 916 Imatinib mesylate Tablets IP 400mg 10's Anticancer/Oncology 3 422.0 87 934 Lenalidomide Capsules 10mg 10's Anticancer/Oncology 0 88 935 Letrozole Tablets 2.5mg 10's 42.40 Anticancer/Oncology 1988. 89 936 Leuprolide Acetate Injections 3.75mg 1's 1's Anticancer/Oncology 00 430.0 90 994 Oxaliplatin Injections 50mg Vial Vial Anticancer/Oncology 0 16.7ML 540.0 91 997 Paclitaxel Injection IP 100mg (6mg/ml) Vial Anticancer/Oncology Vial 0 92 1096 Vincristine Injection IP 1mg 1 ml 1ml 25.00 Anticancer/Oncology 93 1183 Cyclophosphamide 500 mg injection VIAL vial 35.00 Anticancer/Oncology 94 1199 Hydroxyurea Capsule 500mg 10's 10's 54.00 Anticancer/Oncology 95 133 Glibenclamide 2.5 mg Tablet (Scored Oval) 10's 10's 2.60 Antidiabetic 96 134 Glibenclamide 5 mg Tablet (Scored Oval) 10's 10's 4.05 Antidiabetic 97 135 Gliclazide 40 mg Tablet 10's 10's 11.93 Antidiabetic 98 136 Gliclazide 80 mg Tablet 10's 10's 20.25 Antidiabetic 99 137 Glimeperide Tablets IP 1mg 10's 10's 4.38 Antidiabetic 100 138 Glimeperide Tablets IP 2mg 10's 10's 5.05 Antidiabetic
Recommended publications
  • Medical Review(S) Clinical Review

    Medical Review(S) Clinical Review

    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
  • Ocps) Used in the NM Family Planning Program (FPP

    Ocps) Used in the NM Family Planning Program (FPP

    The following slides are intended to familiarize nurses and clinicians with oral contraceptive pills (OCPs) used in the NM Family Planning Program (FPP). The FPP does not intend for this information to supersede the Family Planning Protocol particularly on the requirement for Public Health Nurses in the Public Health Offices to consult a clinician as stated in the Protocol when in doubt or if it is necessary to switch the client’s OCP type. 1 2 Combined oral contraceptives (COCs) contain two hormones; estrogen and progestin. In general, any combined OCP is good for most women who are eligible to take estrogen according to the CDC U.S. Medical Eligibility Criteria (MEC). Once again, refer to the US MEC chart to find out if OCP is a suitable choice for clients with specific health conditions. To learn a little bit about what each hormone does, the FPP is providing the following summary: Estrogen: provides endometrial stability = menstrual cycle control. A higher estrogen dose increases the venous thromboembolism (VTE) or clot risk but OCP clot risk is still less harmful than the clot risk related to pregnancy and giving birth. Progestin: provides most of the contraceptive effect by ‐Preventing luteinizing hormone (LH) surge /ovulation ‐Thickening the cervical mucus to prevent sperm entry. Two major OCP formations are available. Monophasic: There is only one dose of estrogen and progestin in each active pill in the packet; and Multiphasic: There are varying doses of hormones, particularly progestin in the active pills. 3 Section 3 of the FPP Protocol contains the OCP Substitute Table, which groups OCPs into 6 classes according to the estrogen dosage, the type of progestin and the formulations.
  • Product List March 2019 - Page 1 of 53

    Product List March 2019 - Page 1 of 53

    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
  • Prescription Pattern of Primary Osteoarthritis in Tertiary Medical

    Prescription Pattern of Primary Osteoarthritis in Tertiary Medical

    Published online: 2020-04-21 Running title: Primary Osteoarthritis Nitte University Journal of Health Science Original Article Prescription Pattern of Primary Osteoarthritis in Tertiary Medical Centre Sowmya Sham Kanneppady1, Sham Kishor Kanneppady2, Vijaya Raghavan3, Aung Myo Oo4, Ohn Mar Lwin5 1Senior Lecturer and Head, Department of Pharmacology, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 2Senior Lecturer, School of Dentistry, International Medical University, Kuala Lumpur, Malaysia, 3Head of the Department of Pharmacology, KVG Medical College and Hospital, Kurunjibag, Sullia, Karnataka, India. 4Assistant Professor, Department of Biochemistry, Faculty of Medicine, Lincoln University College, Selangor Darul Ehsan, Malaysia, 5Post graduate student, Department of Physiology, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia. *Corresponding Author : Sowmya Sham Kanneppady, Senior Lecturer and Head,Department of Pharmacology, Faculty of Medicine, Lincoln University College, No. 2, Jalan Stadium, SS 7/15, Kelana Jaya, 47301, Petaling Jaya, Selangor Darul Ehsan, Malaysia. E-mail : [email protected]. Received : 12.10.2017 Abstract Review Completed : 05.12.2017 Objectives: Osteoarthritis (OA) is one of the commonest joint/musculoskeletal disorders, Accepted : 06.12.2017 affecting the middle aged and elderly, although younger people may be affected as a result of injury or overuse. The study aimed to analyze the data, evaluate the prescription pattern and Keywords: Osteoarthritis, anti- rationality of the use of drugs in the treatment of primary OA with due emphasis on the inflammatory agents, prevalence available treatment regimens. Materials and methods: Medical case records of patients suffering from primary OA attending Access this article online the department of Orthopedics of a tertiary medical centre were the source of data.
  • Use of Chemical Chelators As Reversal Agents for Drug

    Use of Chemical Chelators As Reversal Agents for Drug

    (19) TZZ_ _ZZZ_T (11) EP 1 210 090 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 31/724 (2006.01) A61K 31/194 (2006.01) 18.06.2014 Bulletin 2014/25 A61P 39/04 (2006.01) (21) Application number: 00964006.1 (86) International application number: PCT/EP2000/007694 (22) Date of filing: 07.08.2000 (87) International publication number: WO 2001/012202 (22.02.2001 Gazette 2001/08) (54) USE OF CHEMICAL CHELATORS AS REVERSAL AGENTS FOR DRUG- INDUCED NEUROMUSCULAR BLOCK VERWENDUNG VON CHEMISCHEN CHELATOREN ZUR UMKEHRUNG VON PHARMAKOLOGISCH-INDUZIERTER NEUROMUSKULÄRER BLOCKIERUNG UTILISATION D’AGENTS CHIMIQUES CHELATANTS COMME AGENTS DE NEUTRALISATION DU BLOCAGE NEUROMUSCULAIRE PROVOQUE PAR DES MEDICAMENTS (84) Designated Contracting States: (56) References cited: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU AU-A- 3 662 895 MC NL PT SE • B DESIRE: "Inactivaton of sarin and soman by (30) Priority: 13.08.1999 EP 99306411 cyclodextrins in vitro" EXPERIENTIA, vol. 43, no. 4, 1987, pages 395-397, XP000907287 (43) Date of publication of application: • B. DESIRE: "Interaction of soman with beta- 05.06.2002 Bulletin 2002/23 cyclodextrin" FUNDAMENTAL AND APPLIED TOXICOLOGY, vol. 7, no. 4, 1986, pages 647-657, (73) Proprietor: Merck Sharp & Dohme B.V. XP000911170 2031 BN Haarlem (NL) • C. MAY: "Development of a toxin-binding agent as a treatment for tunicamycinuracil toxicity: (72) Inventors: protection against tunicamycin poisoning of • BOM, Antonius, Helena, Adolf sheep" AUSTRALIAN VETERINARY JOURNAL, Ratho, Midlothian EH28 8NY (GB) vol. 76, no.
  • WHO Pharmaceuticals Newsletters

    WHO Pharmaceuticals Newsletters

    2021 WHO Pharmaceuticals No.1 NEWSLETTER The WHO Pharmaceuticals Newsletter provides you with the latest information on the safety of medicines WHO Vision for Medicines Safety and legal actions taken by regulatory authorities around No country left behind: the world. It also provides signals based on information worldwide pharmacovigilance for safer medicines, safer patients derived from the WHO global database of individual case safety reports, VigiBase. In addition, this edition of the Newsletter includes a The aim of the Newsletter is to disseminate regulatory summary of discussions and key recommendations of information on the safety of Advisory Committee on Safety of Medicinal Products pharmaceutical products, (ACSoMP) Seventeenth meeting. based on communications received from our network of national pharmacovigilance centres and other sources such as specialized bulletins and journals, as well as partners in WHO. The information is produced in the form of résumés in English, full texts of which may be obtained on request from: Safety and Vigilance: Medicines, EMP-HIS, World Health Organization, 1211 Geneva 27, Switzerland, Contents E -mail address: [email protected] This Newsletter is also available at: Regulatory matters http://www.who.int/medicines Safety of medicines Signal Feature WHO Pharmaceuticals Newsletter No. 1, 2021 ISBN 978-92-4-002136-5 (electronic version) ISBN 978-92-4-002137-2 (print version) © World Health Organization 2021 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below.
  • Download Document

    Download Document

    FAM001159-0001 intervals of 4-7 days to usual dose of 75-100 mg Dolmatil® (Sanofi-Synthelabo) ~ 100 rag/5 mL, thioridazine 100 rag/ per course and max. 4 injections; max. duration of daily according to response; CHILD not recom- Tablets, both scored, sulpiride 200 rag, net price ’ net price 300 mL = £7.14. Label: 2 treatment 2 weeks---if maintenance treatment mended 100-tabpack=£13.85;400mg(f/c), 100-tab ! fNote. These suspensions should not be diluted but the necessary change to an oral antipsychotic 2-3 Short-term adjunctive management of severe pack = £36¯29. Label: 2 .: :~t~a preparations may be mixed with each other to days after last injection, or to a longer acting anti- anxiety, 15-20rag daily in divided doses; max. Sulpltil® (Pharmacia) I~ ~0iovid¢ intermediate strengths psychotic depot injection given concomitantly 40 mg daily; CHILD not recommended Tablets, scored, sulpiride 200 rag. Net price 28-tab "ff~-~p, brown, thioridazine (as hydrochloride) with last injection of zuclopenthixol acetate; By deep intramuscular injection, psychoses, mania, pack = £4.29; 112-tab pack = £12.85. Label: 2 ~ff.~5"~mg/5 mL, net price 300 mL = £1.98. Label: 2 CHILD not recommended prochlorperazine mesilate 12.5-25 mg 2-3 times Sulpor® (Rosemont) IPoMI Clopi~ol Acuphase® (Lundbeck) daily; CHILD not recommended Oral solution, sugar-free, lemon- and aniseed-fla. LUOPERAZINE Injection (oily), zuclopenthixol acetate 50 mg/mL. By rectum in suppositories, psychoses, mania, the voured, sulpiride 200 mg/5 mL, net price 150 mL (’~’n~ications: see under Dose; anti-emetic (section Net price I-mL amp = £5.20; 2-mL amp = £10.03 equivalent of prochlorperazine maleate 25 mg 2- = £27.00.
  • Research Journal of Pharmaceutical, Biological and Chemical Sciences

    Research Journal of Pharmaceutical, Biological and Chemical Sciences

    ISSN: 0975-8585 Research Journal of Pharmaceutical, Biological and Chemical Sciences Formulation and Evaluation of Floating Drotaverine Hydrochloride Tablets Using Factorial Design Om Prakash*, S Saraf, M Rahman, Neeraj Agnihotri, and Vinay Pathak Department of Industrial chemistry, Integral University, Lucknow. Uttar Pradesh, India. ABSTRACT The main aim of this study was to optimize and evaluate the floating tablets of Drotaverine HCl that prolong the gastric residence time, increasing drug bioavailability and control pain for longer duration by oral administration. A floating drug delivery system(FDDS) was developed using gas forming agent like sodium bicarbonate, citric acid polymers like hydroxypropyl methyl cellulose(HPMC), Sod CMC, Carbopol-934P, PVP K-30. In 32 factorial design amount of HPMC(X1) and gas generating agents(X2) were selected as independent variable and % drug release for 30min,1h, 2h,4h,6h, 8h,12h, 16h , 24h and floating lag time (FLT) were taken as dependent variable. The floating tablet formulations were evaluated for Bulk density (gm/cm3), Tapped density(gm/cm3), Hausner ratio(HR), Carr index, Angle of repose, flow property, assay, in-vitro drug release, hardness, friability,weight variation. The results of in vitro release studies showed that the optimized formulation (F9) could sustain drug release (98.74%) for 24h and remain buoyant for more than 24h. The combination of hydrophilic (HPMC) and hydrophobic (carbopol-934P) polymer provides a better option for 24h release action, bioavailability, stability of tablets at 400C/75%RH, of optimized formulation was carried for one month and no significant change was observed. Keywords: floating drug delivery system(FDDS), Drotaverine HCl, gas generating agents, floating lag time (FLT), hydrophilic (HPMC) and hydrophobic (carbopol-934P) polymer.
  • 12-6202 Document: 01018895054 Date Filed: 08/10/2012 Page: 1 FILED United States Court of Appeals UNITED STATES COURT of APPEALS Tenth Circuit

    12-6202 Document: 01018895054 Date Filed: 08/10/2012 Page: 1 FILED United States Court of Appeals UNITED STATES COURT of APPEALS Tenth Circuit

    Appellate Case: 12-6202 Document: 01018895054 Date Filed: 08/10/2012 Page: 1 FILED United States Court of Appeals UNITED STATES COURT OF APPEALS Tenth Circuit FOR THE TENTH CIRCUIT August 10, 2012 Elisabeth A. Shumaker Clerk of Court MICHAEL EDWARD HOOPER, Plaintiff-Appellant, v. No. 12-6202 (D.C. No. 5:12-cv-00758-M) JUSTIN JONES, Director DOC; (W.D. Okla.) RANDALL G. WORKMAN, Warden; DOES, Unknown Executioners, Defendants-Appellees. ORDER AND JUDGMENT* Before MURPHY, O’BRIEN, and HOLMES, Circuit Judges. Michael Edward Hooper, an Oklahoma state prisoner scheduled for execution by lethal injection on August 14, 2012, appeals from the district court’s order * After examining the briefs and appellate record, this panel has determined unanimously that oral argument would not materially assist the determination of this appeal. See Fed. R. App. P. 34(a)(2); 10th Cir. R. 34.1(G). The case is therefore ordered submitted without oral argument. This order and judgment is not binding precedent, except under the doctrines of law of the case, res judicata, and collateral estoppel. It may be cited, however, for its persuasive value consistent with Fed. R. App. P. 32.1 and 10th Cir. R. 32.1. Appellate Case: 12-6202 Document: 01018895054 Date Filed: 08/10/2012 Page: 2 denying his motion for a preliminary injunction seeking to stay his execution. Exercising jurisdiction under 28 U.S.C. § 1292(a)(1), we AFFIRM.1 I Mr. Hooper was tried and convicted on three counts of first-degree murder and sentenced to death. See Hooper v. State, 947 P.2d 1090 (Okla.
  • Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In

    Comparing the Effects of Combined Oral Contraceptives Containing Progestins with Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis In

    JMIR RESEARCH PROTOCOLS Amiri et al Review Comparing the Effects of Combined Oral Contraceptives Containing Progestins With Low Androgenic and Antiandrogenic Activities on the Hypothalamic-Pituitary-Gonadal Axis in Patients With Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis Mina Amiri1,2, PhD, Postdoc; Fahimeh Ramezani Tehrani2, MD; Fatemeh Nahidi3, PhD; Ali Kabir4, MD, MPH, PhD; Fereidoun Azizi5, MD 1Students Research Committee, School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 2Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 3School of Nursing and Midwifery, Department of Midwifery and Reproductive Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, Tehran, Islamic Republic Of Iran 5Endocrine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic Of Iran Corresponding Author: Fahimeh Ramezani Tehrani, MD Reproductive Endocrinology Research Center Research Institute for Endocrine Sciences Shahid Beheshti University of Medical Sciences 24 Parvaneh Yaman Street, Velenjak, PO Box 19395-4763 Tehran, 1985717413 Islamic Republic Of Iran Phone: 98 21 22432500 Email: [email protected] Abstract Background: Different products of combined oral contraceptives (COCs) can improve clinical and biochemical findings in patients with polycystic ovary syndrome (PCOS) through suppression of the hypothalamic-pituitary-gonadal (HPG) axis. Objective: This systematic review and meta-analysis aimed to compare the effects of COCs containing progestins with low androgenic and antiandrogenic activities on the HPG axis in patients with PCOS.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • Quantitative Analysis of the Aminosteroidal Muscle Relaxant

    Quantitative Analysis of the Aminosteroidal Muscle Relaxant

    J. Ecophysiol. Occup. Hlth. 3 & 4 (2013) 29-37 ® 2013 The Academy of Environmental Biology, India Quantitative Analysis of the Aminosteroidal Muscle Relaxant Vecuronium in Rat Liver and Kidneys using Ion-pairing and Liquid Chromatography-Tandem Mass Spectrometry Risha Jasmine Nathan*, P. Sharma, Lily Saroj Nathan1 Forensic Chemistry and Toxicology, Lok Nayak Jayaprakash Narayan National Institute of Criminology, New Delhi 1Ewing Christian College, University of Allahabad Abstract : Muscle relaxants are occasionally encountered in forensic toxicological cases for identification and quantitation. Due to unavailability of human samples, the analysis of the muscle relaxant vecuronium was done using post-mortem rat visceral samples. Rats were injected with bolus overdose of the drug and the post mortem samples were subject to ion-pair extraction with metanil yellow dye. Method for identification of the drug by LC-MS-MS was established first with secondary standard aqueous vecuronium solutions and then applied on the questioned samples. Quantitation was done to find the quantity of the drug in liver and kidney samples. Keywords : Aminosteroid, Muscle relaxant Vecuronium, Liquid Chromatography-Tandem Mass Spectrometry. Introduction ventilation is made available to the patient so as Muscle relaxants, better known as neuro- to maintain respiration as these drugs may also muscular-blocking drugs, are a class of drugs paralyze the diaphragm at the therapeutic dose that block neuromuscular transmission at required (Dripps, 1959). Despite taking neuromuscular junction which causes paralysis precautions, neuromuscular blocking drugs of the affected skeletal muscles. Of the two have been reported to have inadvertently classes, non-depolarizing neuromuscular caused deaths of patients by accident agents work without depolarizing the motor end (Newsletters, Nurse Advise, 2006).